Jason Fontenot
No más puestos en curso
Fortuna: 68 544 $ al 30/04/2024
Perfil
Jason D.
Fontenot worked as the Chief Scientific Officer & Senior Vice President at Sangamo Therapeutics, Inc. from 2021 to 2024.
Prior to that, he was the Chief Scientific Officer at Immusoft Corp.
from 2018 to 2019 and the Head-Exploratory Research at Juno Therapeutics, Inc. from 2016 to 2018.
He earned a doctorate degree from the University of Washington.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 25/11/2023 | 136 270 ( 0.07% ) | 68 544 $ | 30/04/2024 |
Antiguos cargos conocidos de Jason Fontenot.
| Empresas | Cargo | Fin |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 02/01/2024 |
Immusoft Corp.
 Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Director Técnico/Científico/I+D | 01/03/2019 |
| JUNO THERAPEUTICS INC | Director Técnico/Científico/I+D | 01/01/2018 |
Formación de Jason Fontenot.
| University of Washington | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Immusoft Corp.
Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Health Services |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
- Bolsa de valores
- Insiders
- Jason Fontenot
